Novartis AG (NYSE:NVS)‘s stock had its “neutral” rating reiterated by analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Monday.

A number of other equities analysts also recently commented on the company. Cowen and Company set a $77.00 price target on Novartis AG and gave the stock a “hold” rating in a research note on Tuesday, July 11th. Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Credit Suisse Group cut shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price on the stock. in a report on Wednesday, July 5th. Leerink Swann reissued a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a report on Thursday, June 22nd. Finally, Barclays PLC raised shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a report on Thursday, June 22nd. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $81.71.

Novartis AG (NYSE NVS) traded up 0.46% on Monday, reaching $85.16. The company had a trading volume of 995,677 shares. The firm has a 50-day moving average of $82.65 and a 200-day moving average of $77.25. The stock has a market capitalization of $201.45 billion, a P/E ratio of 32.02 and a beta of 0.73. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90.

Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.46% and a net margin of 13.10%. The company’s revenue was down 1.8% on a year-over-year basis. During the same period last year, the firm earned $1.23 earnings per share. On average, equities research analysts expect that Novartis AG will post $4.72 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “J P Morgan Chase & Co Reiterates Neutral Rating for Novartis AG (NYSE:NVS)” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/j-p-morgan-chase-co-reiterates-neutral-rating-for-novartis-ag-nysenvs/1453084.html.

In other Novartis AG news, major shareholder Bioventures Ltd Novartis purchased 266,667 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.01% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of NVS. BTIM Corp. raised its position in Novartis AG by 2.7% in the second quarter. BTIM Corp. now owns 45,160 shares of the company’s stock valued at $3,769,000 after buying an additional 1,200 shares during the period. Sit Investment Associates Inc. boosted its position in Novartis AG by 3.2% in the second quarter. Sit Investment Associates Inc. now owns 18,995 shares of the company’s stock valued at $1,586,000 after buying an additional 595 shares during the last quarter. Aperio Group LLC boosted its position in Novartis AG by 8.7% in the second quarter. Aperio Group LLC now owns 757,486 shares of the company’s stock valued at $63,227,000 after buying an additional 60,773 shares during the last quarter. West Coast Financial LLC boosted its position in Novartis AG by 2.3% in the second quarter. West Coast Financial LLC now owns 7,460 shares of the company’s stock valued at $623,000 after buying an additional 165 shares during the last quarter. Finally, North Star Investment Management Corp. boosted its position in Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after buying an additional 16 shares during the last quarter. Hedge funds and other institutional investors own 11.29% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.